.png)
SummaryGermany's 2026 pharmaceutical pricing reform, the GKV-Beitragssatzstabilisierungsgesetz (BStabG), raises the statutory manufacturer discount to 15.5 percent, lifts the pharmacy fixed fee to 9.00 euro from 1 July 2026, tightens the price moratorium with an inflation adjustment, and adds new interventions in the patent market. For manufacturers, wholesalers and pharmacies operating in the German market, it is the most consequential change to statutory pricing mechanics in years, and much of it takes effect between 1 July 2026 and 1 January 2027.
The BStabG, formally the GKV-Beitragssatzstabilisierungsgesetz, is a cost-containment law passed by the German Bundestag on 10 July 2026. Its stated purpose is to stabilise statutory health insurance (GKV) contribution rates by closing a large financing gap, and it combines spending cuts with revenue measures across hospitals, physicians and pharmaceuticals. On the drug-pricing side it reworks several long-standing instruments at once, which is why market-access, wholesale and pharmacy teams need to read it as a package rather than a single rate change.
The reform targets nearly 19 billion euro in statutory health insurance savings for 2027 alone, according to the Federal Ministry of Health.
The pharmaceutical measures sit inside the German social code, primarily Section 130a SGB V (manufacturer discount and price moratorium) and Section 130 SGB V (the pharmacy discount to the funds), plus the pharmacy price ordinance (AMPreisV) for the dispensing fee. If you are new to how these fit together, our primer on how drug pricing works in Germany sets out the base architecture the BStabG now amends.
The reform moves five pricing levers. The table below summarises what changes, when it takes effect, and the legal basis, so teams can map each item to their own price files.
| Instrument | Before | After BStabG | Effective | Legal basis |
|---|---|---|---|---|
| Manufacturer discount (Herstellerabschlag) | 7 percent | 15.5 percent, fixed (7 percent base plus 8.5 percent additional) | 1 January 2027 | Section 130a SGB V |
| Pharmacy fixed fee (Apothekenfixum) | 8.35 euro | 9.00 euro, then 9.50 euro | 1 July 2026, then 1 January 2027 | AMPreisV |
| Pharmacy discount to the funds (Apothekenabschlag) | 1.77 euro | 2.07 euro | 1 January 2027 | Section 130 SGB V |
| Price moratorium inflation adjustment | Reference prices frozen | Adjustment of plus 2.2 percent for 2026 | 2026 (annual) | Section 130a Abs. 3a SGB V |
| Patent-market rebate tenders | Combination discount | Competitive tenders for comparable patent actives | Pilot to 31 December 2030 | Section 130e SGB V |
The statutory manufacturer discount increases from 7 percent to 15.5 percent, effective 1 January 2027. It is structured as the existing 7 percent base plus a new 8.5 percent additional discount, and it applies as a deduction the manufacturer grants on the pharmacy sales price of most patent-protected prescription products. Notably, the government's original draft proposed a dynamic surcharge starting at 3.5 percent and recalculated annually. Parliament replaced that mechanism with a fixed rate, so the final figure is static and plannable rather than variable year to year. A separate location clause (Standortklausel), intended to grant relief to companies conducting research and production in Germany, was moved into follow-up legislation rather than being included in the main law. For patented vaccines, the reform raises the discount to 9 percent and imposes a price freeze from January 2027 through December 2030.
The pharmacy fixed fee (Apothekenfixum), the per-package amount a pharmacy earns on a prescription regardless of the product's price, rises from 8.35 euro net to 9.00 euro net on 1 July 2026, and then to 9.50 euro net on 1 January 2027. This is the first increase to the dispensing fee since 2013. In parallel, the pharmacy discount granted to the health funds (Apothekenabschlag) increases from 1.77 euro to 2.07 euro per package from 1 January 2027, under Section 130 SGB V. The two changes move in opposite directions for the funds: the higher fixed fee raises the acquisition cost of almost every package, while the larger fund discount claws part of that back. Because the fixed fee is a structural component, it re-prices the majority of packages on the market without any manufacturer changing a list price.
Germany has maintained a price moratorium (Preismoratorium) that freezes manufacturer reference prices at a historical baseline, offset by an annual inflation adjustment. Under Section 130a Abs. 3a SGB V, the adjustment for 2026 is plus 2.2 percent, corresponding to the annual average consumer price index for 2025. The BStabG also tightens how the moratorium baseline is applied: the reference now extends to any market-present product sharing the same active ingredient and a comparable dosage form, rather than being tied to a single manufacturer's own historical price. For pricing teams, the practical effect is that the permitted headroom on affected products is defined by a moving, cross-manufacturer reference, which needs to be tracked against each product's current price.
Beyond the headline discount, the reform introduces mechanisms aimed specifically at patent-protected medicines. The most structural is a new competitive tender route under Section 130e SGB V: health funds may run tenders for patent-protected active ingredients that are therapeutically comparable, replacing the earlier combination-discount approach. This runs as a pilot across five therapeutic classes until 31 December 2030, covering PD-1 and PD-L1 inhibitors in oncology, PCSK9 inhibitors in cardiology, PARP inhibitors, JAK inhibitors, and CGRP antagonists in migraine. Alongside the tender route sits the tightened price moratorium described above. Together these signal a shift toward active price competition inside the patent segment, an area that was historically shielded from substitution pressure. The five pilot classes were chosen because each contains several patent-protected molecules with broadly comparable therapeutic effect, which is what makes a tender feasible. Manufacturers active in those classes should expect price to become a live variable in fund decisions well before loss of exclusivity. For a fuller picture of the reimbursement side, including the value-based mechanics that sit upstream of these prices, see our overview of the AMNOG reimbursement database.
The reform is phased, and the two anchor dates are 1 July 2026 and 1 January 2027.
The Federal Ministry of Health announcement confirms the passage and the core dates.
For manufacturers, the fixed 15.5 percent discount lands directly on net revenue for most patent-protected products, and the tightened moratorium narrows pricing flexibility further. Because the rate is now static rather than dynamic, forecasting is simpler, but the absolute margin impact is larger and, for the affected vaccine segment, compounded by a multi-year price freeze. Industry associations have warned that the combined burden could weigh on launch decisions and on Germany's attractiveness as a research location, a concern the German association of research-based pharmaceutical companies has raised publicly.
For wholesale, the changes flow through purchasing and settlement systems on the two effective dates, and the shifting fixed fee and fund discount both touch the calculation of what is invoiced and rebated per package. For pharmacies, the higher fixed fee improves the per-package margin for the first time in over a decade, partly offset by the larger discount granted to the funds. Across all three, the operational challenge is the same: every affected price and rebate has to be correct on the exact cut-off date, per product, or downstream settlements will not reconcile. The reform has also drawn international attention, given Germany's role as a reference market whose ex-factory prices feed into other countries' pricing rules, which means the changes are being watched well beyond the domestic supply chain.
Reforms of this kind live or die on data accuracy at the package level. In the German market, prices and their reimbursement context are keyed to the PZN (Pharmazentralnummer) and built on the official ABDA article master data (ABDA-Artikelstamm). pharmazie.com carries this pricing and reimbursement context per PZN, delivers price-change data through a REST API and structured data export, and monitors the statutory price cut-off dates so that changes such as the 1 July 2026 fixed-fee step and the 1 January 2027 discount change surface against the correct effective date. That lets pricing, market-access and procurement teams reconcile what applies on a given day rather than reconstructing it after the fact.
The platform consolidates more than 25 databases in a single search, spanning over 50,000 German products and more than 120,000 international products across 50-plus countries, and DACON has maintained this data infrastructure since 1989. For teams whose questions span both the German pricing mechanics changed by the BStabG and cross-border comparisons, our companion piece on pharma pricing in Germany goes deeper on the day-to-day mechanics. The BStabG changes the numbers; the discipline is making sure your systems hold the right number on the right date.
This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.
